Article Text


Long term outcome after subarachnoid haemorrhage of unknown aetiology
  1. Liisa M Pyysalo1,
  2. Tero T Niskakangas1,
  3. Leo H Keski-Nisula2,
  4. Veikko J Kähärä2,
  5. Juha E Öhman1
  1. 1Tampere University Hospital, Department of Neurosurgery, Tampere, Finland
  2. 2Medical Imaging Centre, Tampere, Finland
  1. Correspondence to Dr L M Pyysalo, Tampere University Hospital, Department of Neurosurgery, P O Box 2000, Tampere FIN-33521, Finland; liisa.pyysalo{at}


Background and purpose The aim of this study was to assess the long term outcome after non-aneurysmal subarachnoid haemorrhage (SAH).

Methods 1154 patients with SAH were treated in our hospital between 1989 and 1999. From this patient population, 97 patients had a non-aneurysmal SAH. All hospital records and death certificates were studied and 33 patients were examined by MRI and MR angiography more than 9 years (mean 12 years) after the initial bleeding.

Results The cohort consisted of 97 patients. Mean follow-up time was 9 years (range 0–19). During the follow-up period, 13 patients (13%) died. Four (4%) died from the initial bleeding less than 5 weeks after the initial haemorrhage. There was no delayed mortality due to SAH or subsequent bleedings. MR angiography revealed no new findings in 33 surviving patients.

Conclusions Excess mortality during the first year after SAH was higher than 4%, and remained thereafter comparable with the general population. There were no rebleedings and MR imaging did not reveal any vascular pathology that could explain the earlier SAH.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: and

Statistics from


On average, in 15% (5–30%) of patients with spontaneous subarachnoid haemorrhage (SAH), no obvious source of bleeding can be demonstrated, even with high quality four vessel cerebral digital subtraction angiography (DSA).1–8 The cause of angiogram negative SAH has not been established but a venous or capillary source, ruptured perforating artery, low flow vascular malformation and short segment arterial dissection have all been postulated.9–11 Some researchers do not accept this and speculate that spontaneous thrombosis, vasospasm, destruction of the aneurysm by haemorrhage, narrowing of the aneurysmal neck, alterations in blood flow, inadequate angiographic technique or observer error may be responsible.2 Outcome of angiogram negative SAH is good in 90% of cases.4 7 8 12 13 However, many groups report non-specific symptoms such as headache, neuropsychological deficits or depressive symptoms in up to 62% of patients.14–16 The rebleeding rate is approximately 5% (0–10%)7 8 15–18 and the risk of death in non-aneurysmal bleeding has been estimated to be 0–15%2 4 7 8 12 13 15 17 18 Greebe and Rinkel15 concluded that patients with an angiographic negative perimesencephalic pattern of SAH have a normal life expectancy but Hawkins et al17 found the cumulative proportional survival after 22 years to be 69% compared with an expected survival of 89% in patients with SAH of unknown aetiology.

To the best of our knowledge there are no studies analysing intracranial arterial status very long after initial bleeding or that have reported the incidence of de novo aneurysms in patients having SAH of unknown aetiology. The aim of this study was to assess long term outcome after non-aneurysmal SAH.



Our hospital serves as a primary and secondary care centre for patients with SAH, with a catchment area of more than 1 million. Between 1989 and 1999, a total of 1154 patients with symptoms and signs of spontaneous, non-traumatic SAH were admitted to our hospital. Of these, 97 (8.4%) patients were included in the study because the aetiology of the SAH could not be verified by repeated four vessel cerebral angiography or postmortem examination. SAH was diagnosed by CT in 80 (82%) cases and by a blood positive lumbar puncture in 17 (18%) cases. The diagnosis ‘SAH NOS’ was based on DSA in 96 patients and postmortem examination in one patient. All hospital records were studied and the latest outcome of patients was evaluated from the most recent notes in the hospital records or by telephone interview. Clinical status at the time of the bleeding was assessed according to the Hunt and Hess scale.19 Glasgow Outcome Scale (GOS)20 was used to evaluate clinical status at the time of discharge and at follow-up visits. Primary CT images were re-evaluated to assess Fisher grades and the presence of hydrocephalus. All angiograms were reviewed independently by a neuroradiologist, neurointerventionalist and neurosurgeon. Thereafter, the results were reviewed and a consensus statement for each study was produced. Surviving patients resident in our hospital catchment area were contacted, offered an MRI examination and interviewed to assess clinical outcome and possible rebleeding episodes. A total of 33 were studied with MRI and MR angiography (MRA), and interviewed at our outpatient clinic. Follow-up MRI and MRA were compared with the findings of earlier studies. Surviving patients not studied with MRI lived outside our hospital catchment area, did not answer our letter, were unwilling to participate in the study or had contraindications to MRI. Two surviving patients were lost to clinical follow-up. Thirteen of 97 patients died, and death certificates were obtained from Statistics Finland. The study was approved by the Hospital Ethics Committee and Statistics Finland.

MRI protocol

The follow-up MR imaging was performed with the 1.5 T unit (GE Signa HD, Milwaukee, USA) with one channel head coil. MRA was supplemented with cross sectional imaging, including fluid attenuation inversion recovery, and T1 and T2* sequences, mainly to identify ischaemic parenchyma, ascertain the size of the CSF spaces and persisting blood degradation deposits. The imaging parameters for the non-contrast three-dimensional time of flight angiography were: TR 30, TE 2.5, FOV 22×16.5 cm, slice thickness 1.0 mm/interpolated to 0.5 mm, matrix 320×224. Magnetisation transfer contrast and flow compensation were included.

Statistical analysis

Statistical analysis was performed using NCSS (NCSS, Kaysville, Utah, USA) statistical software. Categorical variables were compared using the Fisher exact two tailed test. The level of significance was set at p<0.05. Excess mortality of the patients was measured by one relative survival ratio. The relative survival ratio is the ratio of the actuarial observed survival rate divided by expected survival rate of a comparable group of patients from the Finnish general population matched by sex, age and calendar time. Relative survival measures the survival experience of the patients corrected for competing risks of death. Relative survival ratios were estimated by survival package SURV3 V.3.01 (Finnish Cancer Registry, Helsinki, Finland).


Patients were aged 21–76 years (mean 52) at the time of bleeding. There were 35 men and 62 women. Most patients had a good clinical status on admission (table 1). In the deceased group, patients had a poorer clinical status and higher Fisher grades on primary CT compared with the surviving group. There was no other statistically significant difference between the surviving and deceased groups.

Table 1

Population characteristics

Thirteen of 97 patients (13%) died during the 868 patient-year follow-up period. Four (4%) died from the initial bleeding of the non-aneurysmal SAH: two immediately and two patients in 1 month after a poor clinical state. All four patients had severe bleeding on the initial CT (Fisher 3 or 4, non-perimesencephalic type of bleeding). Three patients died of cardiovascular diseases, three of malignancies and three due to traumatic causes. Mortality in the first year after bleeding was more than 4% in excess of that expected in a comparable group from the general population, both among women and men. Thereafter, mortality of the patients was close to the level in the general population. There were no rebleedings. Ninety-four per cent of the surviving group (79/84) had recovered well (GOS 4 or 5) and the reason for the lower GOS was related to SAH in only two (2%) patients (figure 1). There was no difference in outcome between patients studied with and without MRI.

Figure 1

Present Glasgow Outcome Score (GOS) of patients with subarachnoid haemorrhage of unknown aetiology.

Thirty-three patients were studied with MRI. Mean follow-up time was 12 years (range 9–18). No new aneurysms were detected in MRA images or any other vascular pathology that could explain the previous bleeding. Six patients (18%) had infarctions in MRI. Two were already seen during the treatment period after clinically and radiologically proven vasospasm. Four infarctions were not detected in earlier images and only two of those four patients had been treated for clinical stroke. Leukoaraiosis was seen in 11 (34%) patients. Signs of superficial haemosiderin were present in two patients (6%).


After SAH, initial angiographic findings are negative for a bleeding source in approximately 15% of patients.1–8 A traditional concept states that angiogram negative SAH carries a more benign prognosis than aneurysmal SAH. However, some patients experience morbidity and mortality because of recurrent haemorrhage or vasospasm.14 21–23 Repeat DSA within 2 weeks after the bleeding is commonly performed. Although repeat DSA provides identification of the source of bleeding in up to 20% of cases, the source remains undetected in the majority of patients.22–24 The incidence of angiogram negative SAH was 8.4% in our series and this concurs with recent series.1–8

We found no new arterial vasculopathies or other aetiologies for previous SAH in those 33 patients studied. It is a weakness of our study that we performed MRI in only 34% of patients. However, those surviving patients we could not reach had a poorer clinical status and we believe that this selection bias is unlikely to influence the MRI findings. Infarctions were detected in six (18%) patients, which is significantly less than in patients with aneurysmal SAH.25–27 Two infarctions were caused by vasospasm and two were incidental findings. Leukoaraiosis was seen in 11 (34%) patients and this was less than in aneurysmal SAH patients and not more than the prevalence in a neurologically health age cohort.25–28 Earlier studies of angiogram negative SAH have reported a subsequent bleeding rate of up to 10%.7 8 17 18 29 However, the latest reports have detected no rebleedings and neither did we.15 16

The outcome is much better in SAH patients with unknown aetiology than in aneurysmal SAH patients.2 4 7 8 12 13 15 17 18 Eighty-one per cent of patients had recovered well (GOS 4 or 5) and poor outcome was related to SAH in only six (6%) patients in our series. The risk of death from non-aneurysmal bleeding has been estimated to be 0–15%.2 4 7 8 12 13 15 17 18 In our series, 4% of patients died of angiogram negative SAH. Overall mortality in our series was 13% compared with 47% mortality in aneurysmal SAH patients in our hospital at the same time.30 In the long term outcome study, patients with SAH of unknown cause had reduced life expectancy compared with expected numbers.17 However, in that study, as many as 22% of all SAH patients had no cause on angiogram, which was not repeated, raising the suspicion that aneurysms were missed. Greebe and Rinkel,15 however, found no difference in mortality between the general population and patients with a perimesencephalic pattern of non-aneurysmal SAH. This study was, however, involved only a subgroup of all patients with SAH of unknown aetiology and to the best of our knowledge our study is the only one in the modern imaging modality era to assess the long term outcome of patients with SAH of unknown aetiology.


Excess mortality during the first year after SAH was higher than 4%, and remained thereafter comparable with the general population. There were no rebleedings and MR imaging did not reveal any vascular pathology that could explain the previous SAH. Based on our results, long term follow-up is not needed, and after appropriate angiographic studies, patients should be informed about the benign nature of this rare type of SAH.


The authors would like to thank Tapio Luostarinen, MSc, of the Finnish Cancer Registry for help and advice in statistical problems.


View Abstract


  • Funding The study was financially supported by EVO-funding of Pirkanmaa Health District and Maire Taponen Foundation.

  • Competing interests None.

  • Ethics approval The study was conducted with the approval of the Tampere University Hospital Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.